136 completed, 41 recruiting, 29 unknown, 20 active not recruiting. 53 Phase 2, 37 Not applicable, 33 Phase 1, 29 Phase 3, 14 Phase 4.
Follow Metal Metabolism, Inborn Errors: new trials by email Literature Review of Metal Metabolism, Inborn Errors trials Research Report on Metal Metabolism, Inborn Errors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clarify HPP: Disease Burden of HPP Patients in China Hypophosphatasia (HPP) | Recruiting | AstraZeneca | 200 | 2026-09-26 | 2026-10-29 | |
| Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients. TETA 4HCl formulation, D-Penicillamine - Wilson's Disease | Phase 3 | Recruiting | Orphalan | 38 | 2026-09-03 | 2026-10-15 |
| A Study of the Safety and Efficacy of Prime Editing (PM577) in Participants With Wilson Disease (WD) PM577a - Wilson Disease, Wilson's Disease | Phase 1 / Phase 2 | Recruiting | Prime Medicine, Inc. | 42 | 2026-09-01 | 2026-10-01 |
| Morphology in Oral Rare Syndromes & Artificial Intelligence for Clinical Diagnosis intra-oral 3D optical impression - Osteogenesis Imperfecta, Rare Bone Disorders | Not applicable | Not yet recruiting | University Hospital, Bordeaux | 240 | 2026-09-01 | 2026-06-24 |
| GRACE II (General Retrospective Analysis of Commercial Experience With AGN1 LOEP) AGN1 LOEP - Osteoporosis | Enrolling by invitation | AgNovos Healthcare, LLC | 305 | 2026-08-25 | 2026-10-30 | |
| NORTHERA (DROXIDOPA) for Dysautonomia in Pediatric Survivors of Menkes Disease Droxidopa Oral Product, Placebo Control - Menkes Disease | Phase 1 / Phase 2 | Recruiting | Stephen G. Kaler | 6 | 2026-08-10 | 2026-10-05 |
| Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia methotrexate, rituximab, bortezomib - Hypophosphatasia | Phase 4 | Withdrawn | Alexion Pharmaceuticals, Inc. | 2026-07-29 | 2025-12-18 | |
| Description of Renal Involvement in Wilson's Disease full renal workup - Wilson Disease | Recruiting | Fondation Ophtalmologique Adolphe de Rothschild | 150 | 2026-07-22 | 2026-10-01 | |
| Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a) Setmelanotide - Pseudohypoparathyroidism Type 1a, Obesity | Phase 2 | Enrolling by invitation | Massachusetts General Hospital | 1 | 2026-07-21 | 2026-07-23 |
| Treatment Patterns, Biochemical Profiles and Clinical Outcomes in Adults With X-Linked Hypophosphatemia No treatment given - X-linked Hypophosphatemia (XLH) | Withdrawn | Novo Nordisk A/S | 2026-07-07 | 2026-08-28 | ||
| Endocrine Dysfunction in Pediatric Wilson's Disease Wilson's Disease | Not yet recruiting | Assiut University | 30 | 2026-06-30 | 2025-10-06 | |
| Phase I/II Clinical Study to Evaluate the Safety, Tolerability and Efficacy of LY-M003 Injection in Adult Patients With Wilson's Disease LY-M003 Injection - Wilson's Disease | Phase 1 / Phase 2 | Not yet recruiting | Lingyi Biotech Co., Ltd. | 18 | 2026-06-15 | 2026-07-02 |
| A Study to Evaluate BBI-001 in Healthy Volunteers and in Patients With Hereditary Hemochromatosis BBI-001, Placebo - Hereditary Hemochromatosis | Phase 1 / Phase 2 | Recruiting | Bond Biosciences | 34 | 2026-05-04 | 2026-05-13 |
| Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis Vamifeport, Placebo - Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis | Phase 2 | Active not recruiting | CSL Behring | 84 | 2026-01-22 | 2026-10-21 |
| Off Treatment Urinary Copper Excretion in Wilson Disease, Pilot Study Wilson Disease | Recruiting | Yale University | 30 | 2026-01-08 | 2026-03-05 | |
| A Clinical Study on the Treatment of Wilson Disease With ATP7B mRNA/LNP (DSL101) Group 1: DSL101 Low dose, Group 2: DSL101 Medium dose, Group 3: DSL101 High dose - Wilsons Disease | Early Phase 1 | Recruiting | DSciLab Co., Ltd. | 18 | 2025-12-31 | 2026-01-20 |
| Prescreening Study to Identify Potential Wilson Disease Participants for Gene-Editing Clinical Trial Wilson Disease | Active not recruiting | Prime Medicine, Inc. | 30 | 2025-12-29 | 2026-05-12 | |
| The Effect of Monoallelic Variants in the ALPL Gene on the Natural Course of Hypophosphatasia in Russia Hypophosphatasia | Recruiting | AstraZeneca | 55 | 2025-12-29 | 2026-09-28 | |
| Multifaceted Assessment of Patients With Wilson's Disease in a Low-Resource Setting in Upper Egypt: Service Integration, Psychosocial Burden, Dietary Practices, and the Geo-Spatial Disease Map KAB-pB Scores - Wilson's Disease | Not yet recruiting | Assiut University | 66 | 2025-12-01 | 2025-11-21 | |
| Wilson's Disease Treated With D-Penicillamine: Characterization of Skin Damage Secondary to Treatment by Measuring Skin Elasticity Preparation of forearm molds with SILFLO® silicone - Wilson Disease, D-Penicillamine | Not applicable | Recruiting | Centre Hospitalier Universitaire de Saint Etienne | 120 | 2025-11-28 | 2026-01-23 |
Showing 20 of 265. Sign in to see all of them.
Hepatolenticular Degeneration (79) · Hemochromatosis (54) · Familial Hypophosphatemic Rickets (49) · Hypophosphatasia (46) · Pseudohypoparathyroidism (23) · Iron Overload (19) · Rickets (19) · Osteomalacia (16) · Bone Diseases (14) · Rare Diseases (11) · Hypophosphatemia (9) · Menkes Kinky Hair Syndrome (9) · Thalassemia (8) · Genetic Diseases, Inborn (6) · Hypoparathyroidism (6)
Nutritional and Metabolic Diseases (264) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (263) · Metabolic Diseases (262) · Metabolism, Inborn Errors (261) · Genetic Diseases, Inborn (259) · Musculoskeletal Diseases (99) · Nervous System Diseases (97) · Central Nervous System Diseases (91) · Brain Diseases (90) · Heredodegenerative Disorders, Nervous System (88) · Bone Diseases, Metabolic (87) · Brain Diseases, Metabolic (87) · Brain Diseases, Metabolic, Inborn (87) · Calcium Metabolism Disorders (86)
burosumab (20) · asfotase alfa (16) · Phlebotomy (8) · tetrathiomolybdate (6) · Deferoxamine (5) · Trientine (5) · Deferasirox (4) · Standard of Care (4) · Theophylline (4) · Deferiprone (3) · Penicillamine (3) · Blood Specimen Collection (2) · Calcitriol (2) · Cinacalcet (2) · Dichlorphenamide (2)
Alexion Pharmaceuticals, Inc. (34) · Kyowa Kirin Co., Ltd. (10) · Rennes University Hospital (8) · Fondation Ophtalmologique Adolphe de Rothschild (7) · Assistance Publique - Hôpitaux de Paris (6) · Hospices Civils de Lyon (6) · Kyowa Kirin, Inc. (6) · Orphalan (6) · Yale University (6) · Kyowa Kirin Pharmaceutical Development Ltd (5) · National Heart, Lung, and Blood Institute (NHLBI) (5) · Ultragenyx Pharmaceutical Inc (5) · Vanderbilt University Medical Center (5) · Assiut University (4) · National Center for Research Resources (NCRR) (4)
United States (101) · France (56) · United Kingdom (46) · Germany (34) · Canada (27) · China (24) · Italy (20) · Spain (19) · Australia (17) · Denmark (17) · Japan (13) · Belgium (10) · Netherlands (10) · Poland (10) · Turkey (Türkiye) (10)
Eugene S. Swenson, MD, PhD (4) · Jaclyn Tamaroff, MD (3) · Amy Zhang, PhD (2) · Chaohui Yu, PhD (2) · Curtis Scribner, MD (2) · Eva Rombout, MD (2) · George J. Brewer (2) · Lothar Seefried, MD (2) · Adrian Gadano, MD (1)
PMID 39151033, PMID 26529632, PMID 32417537, PMID 32721016, PMID 32762706, PMID 40962182, PMID 25919461, PMID 27699270, PMID 36854566, PMID 15923132, PMID 16278898, PMID 16675931, PMID 17164301, PMID 17482283, PMID 17652219, PMID 17959863, PMID 18055982, PMID 18252944, PMID 18256395, PMID 18351337, PMID 18752978, PMID 19194885, PMID 19863539, PMID 20497190, PMID 20610593, PMID 20652413, PMID 20658587, PMID 20719837, PMID 21078496, PMID 21183586, PMID 21525160, PMID 21826782, PMID 21848963, PMID 22134099, PMID 22144108, PMID 22180427, PMID 22318199, PMID 22340672, PMID 22397652, PMID 2265118, PMID 23861242, PMID 24030943, PMID 24385534, PMID 24569459, PMID 24914136, PMID 24916507, PMID 25029424, PMID 25281031, PMID 25284616, PMID 25345697
2014 (2), 2025 (2), 2016 (1), 2017 (1), 2018 (1), 2019 (1), K23DK101689 (1), P50AR054086 (1), R01DK088988 (1), R01DK100651 (1), R01DK117354 (1), R01DK137861 (1), R01HL061428 (1), R15HL058203 (1), R21AR061818 (1)